Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir (Q36993483)

17 August 2017

Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir (English)

1 reference

ORCID Public Data File 2021

17 August 2017

1 reference

1 reference

1 reference

1 reference

author name string

Marian Iwamoto

1

1 reference

17 August 2017

Larissa A Wenning

2

1 reference

17 August 2017

Amelia S Petry

3

1 reference

17 August 2017

Martine Laethem

4

1 reference

17 August 2017

Marina De Smet

5

1 reference

17 August 2017

James T Kost

6

1 reference

17 August 2017

Sheila A Breidinger

7

1 reference

17 August 2017

Eric C Mangin

8

1 reference

17 August 2017

Neal Azrolan

9

1 reference

17 August 2017

Howard E Greenberg

10

1 reference

17 August 2017

Wouter Haazen

11

1 reference

17 August 2017

Julie A Stone

12

1 reference

17 August 2017

Keith M Gottesdiener

13

1 reference

17 August 2017

John A Wagner

14

1 reference

17 August 2017

language of work or name

English

0 references

publication date

6 October 2008

1 reference

Antimicrobial Agents and Chemotherapy

17 August 2017

1 reference

17 August 2017

52

1 reference

17 August 2017

12

1 reference

17 August 2017

4338-4343

1 reference

Raltegravir with optimized background therapy for resistant HIV-1 infection

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

Therapeutic drug monitoring in the treatment of HIV-infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

Transcriptional Regulation of Human UGT1A1 Gene Expression: Activated Glucocorticoid Receptor Enhances constitutive Androstane Receptor/Pregnane X Receptor-Mediated UDP-Glucuronosyltransferase 1A1 Regulation with Glucocorticoid Receptor-Interacting P

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2592871

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

20 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18838589

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18838589

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid–liquid extraction and HPLC-MS/MS

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18838589

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.01543-07

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

18838589

1 reference